We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Trade like a pro: Leverage real-time discussions and market-moving ideas to outperform.
The current EMMA market cap is 5.36M. The company's latest EPS is USD -0.1981 and P/E is -13.98.
| Year End 31 December 2022 | 2018 | 2019 | 2020 | 2021 | 2022 |
|---|---|---|---|---|---|
| USD (US$) | USD (US$) | USD (US$) | USD (US$) | USD (US$) | |
| Total Revenue | 1.32M | 22.75M | 23.17M | 20.61M | 18.39M |
| Operating Income | -10.25M | -4.93M | -2.35M | -8.86M | -8.5M |
| Net Income | -9.6M | -54.84M | 1.1M | -15.95M | -10.63M |
| Year End 31 December 2022 | 2018 | 2019 | 2020 | 2021 | 2022 |
|---|---|---|---|---|---|
| USD (US$) | USD (US$) | USD (US$) | USD (US$) | USD (US$) | |
| Total Assets | 5.15M | 59.46M | 59.28M | 56.73M | 48.23M |
| Total Liabilities | 1.87M | 70.51M | 64.69M | 78.18M | 82.32M |
| Total Equity | 3.29M | -11.05M | -5.42M | -21.45M | -34.09M |
| Year End 31 December 2022 | 2018 | 2019 | 2020 | 2021 | 2022 |
|---|---|---|---|---|---|
| USD (US$) | USD (US$) | USD (US$) | USD (US$) | USD (US$) | |
| Operating | -9.04M | -4.52M | -2.45M | -1.25M | -5.07M |
| Investing | -361k | -1.48M | 5.47M | -6.38M | -2.39M |
| Financing | 7.21M | 3.88M | -2.31M | 7.41M | 7.23M |
| Market Cap | 5.36M |
| Price to Earnings Ratio | -13.98 |
| Price to Sales Ratio | 8.08 |
| Price to Cash Ratio | 73.47 |
| Price to Book Ratio | -4.36 |
| Dividend Yield | - |
| Shares Outstanding | 53.64M |
| Average Volume (1 week) | 1.58k |
| Average Volume (1 Month) | 11.22k |
| 52 Week Change | -69.70% |
| 52 Week High | 0.33 |
| 52 Week Low | 0.0506 |
| Spread (Intraday) | 0.04 (29.15%) |
| Company Name | Emmaus Life Sciences Inc (QX) |
| Address |
251 little falls drive wilmington, delaware 19808 |
| Website | https://www.emmausmedical.com |
| Industry | pharmaceutical preparations (2834) |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions
Hot Features
Premium
